Supernus Pharmaceuticals Inc (SUPN)
28.78
-0.19
(-0.66%)
USD |
NASDAQ |
May 15, 14:51
Supernus Pharmaceuticals Cash from Investing (Quarterly): -51.62M for March 31, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -51.62M |
| December 31, 2023 | -65.98M |
| September 30, 2023 | 34.63M |
| June 30, 2023 | 60.30M |
| March 31, 2023 | 239.78M |
| December 31, 2022 | -48.76M |
| September 30, 2022 | -82.23M |
| June 30, 2022 | -15.68M |
| March 31, 2022 | -69.99M |
| December 31, 2021 | 76.13M |
| September 30, 2021 | -5.704M |
| June 30, 2021 | -80.89M |
| March 31, 2021 | -71.44M |
| December 31, 2020 | 49.34M |
| September 30, 2020 | -11.30M |
| June 30, 2020 | -108.18M |
| March 31, 2020 | 35.44M |
| December 31, 2019 | 19.44M |
| September 30, 2019 | -8.355M |
| June 30, 2019 | -65.76M |
| March 31, 2019 | -103.25M |
| December 31, 2018 | 34.33M |
| September 30, 2018 | 25.34M |
| June 30, 2018 | -422.14M |
| March 31, 2018 | -51.01M |
| Date | Value |
|---|---|
| December 31, 2017 | -19.13M |
| September 30, 2017 | -21.16M |
| June 30, 2017 | -25.36M |
| March 31, 2017 | -20.76M |
| December 31, 2016 | -13.64M |
| September 30, 2016 | -10.35M |
| June 30, 2016 | -1.322M |
| March 31, 2016 | -10.65M |
| December 31, 2015 | -12.87M |
| September 30, 2015 | -8.759M |
| June 30, 2015 | -6.54M |
| March 31, 2015 | -11.12M |
| December 31, 2014 | -7.953M |
| September 30, 2014 | 0.524M |
| June 30, 2014 | 6.399M |
| March 31, 2014 | -1.629M |
| December 31, 2013 | 20.91M |
| September 30, 2013 | 4.606M |
| June 30, 2013 | -34.48M |
| March 31, 2013 | -3.149M |
| December 31, 2012 | -9.346M |
| September 30, 2012 | -10.30M |
| June 30, 2012 | -7.757M |
| March 31, 2012 | -21.55M |
| December 31, 2011 | 25.43M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-108.18M
Minimum
Jun 2020
239.78M
Maximum
Mar 2023
-8.542M
Average
-13.49M
Median
Cash from Investing (Quarterly) Benchmarks
| Dynavax Technologies Corp | 2.831M |
| Ligand Pharmaceuticals Inc | -3.775M |
| Pacira BioSciences Inc | -15.53M |
| Esperion Therapeutics Inc | -0.073M |
| Collegium Pharmaceutical Inc | -18.13M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 38.40M |
| Cash from Financing (Quarterly) | 1.57M |
| Free Cash Flow | 99.84M |
| Free Cash Flow Per Share (Quarterly) | 0.6859 |
| Free Cash Flow to Equity (Quarterly) | 38.15M |
| Free Cash Flow to Firm (Quarterly) | 38.15M |
| Free Cash Flow Yield | 6.31% |